912545-86-9
基本信息
SAG.HCI
SAG (Smo agonist)
SAG(Smoothened Agonist)
Smoothened Agonist (SAG)
Smoothened Agonist (SAG) HCl
SAG (cyclopamine antagonist)
3-Chloro-N-[trans-4-(MethylaMino)cyclohexyl]-N-[[3-(4-pyridinyl)phenyl]Methyl]-
3-chloro-N-((1r,4r)-4-(methylamino)cyclohexyl)-N-(3-(pyridin-4-yl)benzyl)benzo[b]thiophene-2-carboxamide
3-Chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[[3-(4-pyridinyl)phenyl]methyl]- benzo[b]thiophene-2-carboxamide
物理化学性质
| 沸点 | 688.6±55.0 °C(Predicted) |
| 密度 | 1.30±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C冷冻 |
| 储存条件 | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | 可溶于 DMSO（高达 20 mg/ml）、DMF（高达 20 mg/ml）或乙醇（高达 20 mg/ml）。 |
| 酸度系数(pKa) | 10?+-.0.40(Predicted) |
| 形态 | 冻干固体 |
| 颜色 | 白色至米色 |
| 水溶解性 | H2O: 20mg/mL, clear |
| 敏感性 | 感光 |
| 稳定性 | 感光 |
| InChIKey | VFSUUTYAEQOIMW-YHBQERECSA-N |
| SMILES | O=C(C1=C(Cl)C2=C(C=CC=C2)S1)N([C@@]3([H])CC[C@@](NC)([H])CC3)CC4=CC(C5=CC=NC=C5)=CC=C4 |
安全数据
| 危险性符号(GHS) |  GHS06 |
| 警示词 | 危险 |
| 危险性描述 | H301-H413 |
| 防范说明 | P273-P301+P310+P330 |
| 危险品运输编号 | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| 海关编码 | 2934999090 |
| 存储类别 | 6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects |
| 危险性类别 | Acute Tox. 3 Oral Aquatic Chronic 4 |
SAG价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-12848 | SAG SAG | 912545-86-9 | 1mg | 600元 |
| 2026/09/15 | HY-12848 | SAG SAG | 912545-86-9 | 5mg | 1800元 |
| 2026/09/15 | HY-12848R | SAG SAG (Standard) | 912545-86-9 | 1 mg | 1600元 |
常见问题列表
EC50: 3 nM (Smo)
SAG (0.1 nM-100 μM; 30 h) induces firefly luciferase expression in Shh-LIGHT2 cells with an EC
50
of 3 nM and then inhibits expression at higher concentrations.
SAG (1-1000 nM; 1 h) competes for the binding of BODIPY-cyclopamine to Smo-expressing Cos-1 cells, yielding an apparent dissociation constant (K
d
) of 59 nM for the SAG/Smo complex.
SAG (100 nM) inhibits the inhibitory effect of ShhN-induced pathway activation by Robotnikinin.
SAG (250 nM; 48 h) significantly increases SMO mRNA and protein expression in MDAMB231 cells.
SAG (250 nM; 24 and 48 h) increases CAXII mRNA expression in MDAMB231 cells at 24h in normoxic and hypoxic conditions in MDAMB231 cells.
SAG (250 nM; 24 h) increases MDAMB231 cells migration.
SAG (1.0 mM) induces more osteogenesis mainly at the defect borders and a significant increase in BV/TV at the eight week timepoint in CD-1 mice.
SAG (15-20 mg/kg; i.p.) induces pre-axial polydactyly prevalently in a dose-dependent manner in mice.
| Animal Model: | Pregnant C57BL/6J mice |
| Dosage: | 15, 17, 20 mg/kg |
| Administration: | A single i.p. |
| Result: | Effective in ca. 80% of the embryos and increased Gli1 and Gli2 mRNA expression in the limb bud, with Gli1 mRNA being the most upregulated at the dose of 20 mg/kg. |